Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28294112 | 0.86 | QPCT (0.53) | PRKCIMMP12QPCT | |
| SCHEMBL9222951 | 0.85 | QPCT (0.50) | PRKCIMMP12QPCTKDM4EMAPT | |
| SCHEMBL763175 | 0.85 | MAPT (0.42) | PRKCIMMP12QPCTKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL29525565 | 0.83 | MAPT (0.42) | PRKCIMMP12QPCTKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL26181295 | 0.83 | MAPT (0.42) | PRKCIMMP12QPCTKDM4EMAPT | |
| SCHEMBL8656478 | 0.82 | DRD2 (0.52) | PRKCIMMP12QPCTKDM4EMAPT | |
| SCHEMBL11784152 | 0.81 | CYP1A2 (0.46) | PRKCIMMP12QPCTKDM4EMAPT | |
| SCHEMBL11089482 | 0.81 | DRD2 (0.51) | PRKCIMMP12QPCTKDM4EMAPT | |
| SCHEMBL11784155 | 0.81 | CYP1A2 (0.46) | PRKCIMMP12QPCTKDM4EMAPT | |
| SCHEMBL2022696 | 0.81 | PRKCI (0.53) | PRKCIMMP12QPCTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107955020-B | Method for synthesizing benzimidazol oxazinone compound by copper salt catalysis in one pot | 西南大学 | 2020-09-22 | — | — | CN | claimed |
| CN-110214141-A | Benzodiazole compound as ENaC inhibitor | 企业治疗学有限公司 | 2019-09-06 | — | — | CN | claimed |
| WO-2017160361-A1 | POLYISOCYANURATE CATALYSTS FOR METAL PANELS AND SPRAY FOAMS | HUNTSMAN PETROCHEMICAL LLC (US) | 2017-09-21 | — | — | WO | claimed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-5271856-A | Heterocyclic nitrogen compound Mannich base derivatives of amino-substituted polymers for oleaginous compositions | EXXON CHEMICAL PATENTS INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5232615-A | Reacting an amine with halogenated polyolefin to form adduct and contacting adduct with an aldehyde and a heterocyclic reactant to form an oil soluble, oxidation resistance dispersant for fuels | EXXON CHEMICAL PATENTS INC. (US) | 1993-08-03 | — | — | US | disclosed |
| US-5211865-A | Oil soluble ethylene copolymer with alpha-olefin and grafted carboxylic acid and anhydride with polyamine, an anhydride and heterocycle | EXXON CHEMICAL PATENTS INC. (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0520012-A1 | IMPROVED MULTIFUNCTIONAL VISCOSITY INDEX IMPROVER-DISPERSANT ANTIOXIDANT (PT-789). | EXXON CHEMICAL PATENTS INC (US) | 1992-12-30 | — | — | EP | disclosed |
| EP-0518949-A1 | NOVEL HETEROCYCLIC NITROGEN COMPOUND MANNICH BASE DERIVATIVES OF AMINO-SUBSTITUTED POLYMERS FOR OLEAGINOUS COMPOSITIONS. | EXXON CHEMICAL PATENTS INC (US) | 1992-12-23 | — | — | EP | disclosed |
| WO-1991013954-A1 | NOVEL HETEROCYCLIC NITROGEN COMPOUND MANNICH BASE DERIVATIVES OF AMINO-SUBSTITUTED POLYMERS FOR OLEAGINOUS COMPOSITIONS | EXXON CHEMICAL PATENTS INC. (US) | 1991-09-19 | — | — | WO | disclosed |
| WO-1991013952-A1 | IMPROVED MULTIFUNCTIONAL VISCOSITY INDEX IMPROVER-DISPERSANT ANTIOXIDANT (PT-789) | EXXON CHEMICAL PATENTS INC. (US) | 1991-09-19 | — | — | WO | disclosed |
| US-4988603-A | RAPID DEVELOPMENT OF SILVER HALIDE PHOTOGRAPHIC MATERIAL; PHOTOSENSITIVITY; HIGH DOT QUALITY | KONICA CORPORATION (JP) | 1991-01-29 | — | — | US | disclosed |
| EP-0324391-A2 | Method for the formation of high-contrast images | KONICA CORPORATION (JP) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | PRKCI 1218/4885MMP12 1066/4885QPCT 4450/4885 |
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | PRKCI 2228/4885MMP12 271/4885QPCT 2378/4885 |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | CPS1, CPSF1, CPSF7 | PRKCI 2048/4885MMP12 1632/4885QPCT 507/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | PRKCI 1218/4885MMP12 1066/4885QPCT 4450/4885 |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | PRKCI 1182/4885MMP12 1622/4885QPCT 2530/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | PRKCI 1660/4885MMP12 4330/4885QPCT 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.